**Author details**

Rania B. Georges1 \*, Hassan Adwan2 and Martin R. Berger1

1 German Cancer Research Center (DKFZ), Heidelberg, Germany

2 German University of Cairo (GUC), Cairo, Egypt

\*Address all correspondence to: r.georges@dkfz-heidelberg.de

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**29**

*Experimental Results Help Shape the Development of Personalized Medicine...*

doxorubicin. Clinical & Experimental

[8] Marinelli A, van Dierendonck JH, van Brakel GM, Irth H, Kuppen PJ, Tjaden UR, et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: Comparison of isolated liver perfusion and hepatic artery infusion. British

[9] Oldenburg J, Begg AC, van Vugt MJ,

Ruevekamp M, Schornagel JH, Pinedo HM, et al. Characterization of resistance mechanisms to cisdiamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Research. 1994;**2**:487-493

[10] Veenhuizen RB, Marijnissen JP, Kenemans P, Ruevekamp-Helmers MC, t Mannetje LW, Helmerhorst TJ, et al. Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. British Journal of Cancer. 1996;**11**:

[11] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics. 2001;**3**:89-95. DOI: 10.1067/

[12] Osanai M, Takasawa A, Murata M, Sawada N. Claudins in cancer: Bench to bedside. Pflügers Archiv/European Journal of Physiology. 2017;**1**:55-67. DOI:

[13] Benczik M, Galamb A, Koiss R, Kovacs A, Jaray B, Szekely T, et al. Claudin-1 as a biomarker of cervical cytology and histology. Pathology Oncology Research. 2016;**1**:179-188. DOI: 10.1007/s12253-015-9990-z

10.1007/s00424-016-1877-7

Metastasis. 2008;**3**:273-282

Journal of Cancer. 1991;**6**:

1069-1075

1387-1392

mcp.2001.113989

*DOI: http://dx.doi.org/10.5772/intechopen.80752*

[1] Arnold M, Sierra MS, Laversanne M,

Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;**4**:683-691. DOI:

[2] Valderrama-Trevino AI, Barrera-Mera B, Ceballos-Villalva JC,

[3] Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Annals of Surgery. 1996;**4**:509-520. discussion

[4] Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Annals of Surgery. 1999;**3**:309-318. discussion 318-321

[5] Wittmer A, Khazaie K,

1999;**5**:369-376

1107-1113

Berger MR. Quantitative detection of lac-Z-transfected CC531 colon carcinoma cells in an orthotopic rat liver metastasis model. Clinical & Experimental Metastasis.

[6] Seelig MH, Leible M, Sanger J, Berger MR. Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.

Oncology Reports. 2004;**5**:

[7] Eyol E, Boleij A, Taylor RR, Lewis AL, Berger

MR. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or

520-502

Montalvo-Jave EE. Hepatic metastasis from colorectal cancer. Euroasian Journal of Hepato-Gastroenterology. 2017;**2**:166-175. DOI: 10.5005/ jp-journals-10018-1241

Soerjomataram I, Jemal A,

**References**

10.1136/gutjnl-2015-310912

*Experimental Results Help Shape the Development of Personalized Medicine... DOI: http://dx.doi.org/10.5772/intechopen.80752*
